This model allowed us to identify a rare mutation in the PIK3R1 gene in a domain that was not expected to be involved in oncogenesis, and showing that this mutation makes ovarian cancer cells responsive to inhibitors of the PI3K/AKT/mTOR pathway. This evidence concerns the gene PIK3CA and ovarian cancer.